In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

Karnataka has long been one of India’s most progressive states in healthcare — home to premier medical institutions, a strong ...

The firm is also calling for measures to support the green transition and the workforce Read more at The Business Times.

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker ...

Researchers discovered that clogged brain “drains” show up early in people at risk of Alzheimer’s disease. These blockages, ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...